Satralizumab clinical trials
Also written SA237 and RG6168.
How each study uses satralizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the satralizumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 14 Aug 2020 · ENSPRYNG · BLA 761149 (FDA, Drugs@FDA)
- European Union
- 24 Jun 2021 · Enspryng · EMEA/H/C/004788 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2022 (4)
| Year | Studies |
|---|---|
| 2014 | 2 |
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 3
Hoffmann-La Roche (11) · International University of Health and Welfare (1) · Massachusetts General Hospital (1) · University of Florida (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 2 in phase 3
Studies that test satralizumab, phase 3 first.
- Dec 2026A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) EncephalitisPhase 3 · Hoffmann-La Roche
- Mar 2027A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)Phase 3 · Hoffmann-La Roche
- Nov 2026A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)Phase 2 · Hoffmann-La Roche
Studies
Open first, then newest update. How each study uses satralizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)RecruitingPhase 3Hoffmann-La RocheNCT05199688Written as SatralizumabHow we know
- Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSDRecruitingPhase 4Massachusetts General HospitalNCT07010302Written as SatralizumabHow we know
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated DiseaseActive, not recruitingPhase 3Hoffmann-La RocheNCT05271409Written as SatralizumabHow we know
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) EncephalitisActive, not recruitingPhase 3Hoffmann-La RocheNCT05503264Written as SatralizumabHow we know
- A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)Active, not recruitingPhase 2Hoffmann-La RocheNCT06450639Written as SatralizumabHow we know
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye DiseaseCompletedPhase 3Hoffmann-La RocheNCT06106828Written as SatralizumabHow we know
- Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye DiseaseCompletedPhase 3Hoffmann-La RocheNCT05987423Written as SatralizumabHow we know
- Satralizumab in the Treatment of Pulmonary Arterial Hypertension (SATISFY-JP Trial)CompletedPhase 2International University of Health and WelfareNCT05679570Written as Satralizumab (Genetical Recombination)How we know
- Satralizumab in Aneurysmal Subarachnoid HemorrhageWithdrawnEarly Phase 1University of FloridaNCT05727657Written as SatralizumabHow we know
- A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia GravisTerminatedPhase 3Hoffmann-La RocheNCT04963270Written as SatralizumabHow we know
- A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An InterventionTerminatedPhase 4Hoffmann-La RocheNCT05269667Written as Satralizumab 120 mgHow we know
- A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)CompletedPhase 3Hoffmann-La RocheNCT04660539Written as satralizumabHow we know
- Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)CompletedPhase 3Hoffmann-La RocheNCT02028884Written as SatralizumabHow we know
- Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)CompletedPhase 3Hoffmann-La RocheNCT02073279Written as SatralizumabHow we know
Codes
What other systems call satralizumab · ClinicalTrials.gg INT001230
- MeSH (NLM) C000655944satralizumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) YB18NF020MSATRALIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 2391541One source FDA
- Wikidata Q58218746satralizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152307SatralizumabOne source FDA
- DrugBank DB15762One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000655944 | satralizumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | YB18NF020M | SATRALIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2391541 | — | One source FDA |
| Wikidata | Q58218746 | satralizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152307 | Satralizumab | One source FDA |
| DrugBank | DB15762 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.